28 August 2017
Stockholm, Sweden – A new study from the FINGER trial team shows that participants with shorter leukocyte telomere length (LTL) had more pronounced benefits on cognition following the multidomain lifestyle intervention.
“These findings are very promising, as individuals with shorter telomeres may represent an at-risk group”, says Dr. Shireen Sindi, lead author of the study based at Karolinska Institute (Sweden) and Imperial College London (UK).
Telomeres are found at the end of chromosomes (which hold our DNA), protecting them from deteriorating or getting tangled up with neighboring chromosomes. Telomeres play an important role in the process of cell division.
The current study is the first to assess whether baseline LTL can modify the effects of a multidomain lifestyle intervention on cognition among older adults who are at risk for cognitive decline. The results showed that the beneficial intervention effects on cognition were more pronounced among individuals with shorter baseline LTL, particularly for executive functioning. Consistent with previous studies, unhealthy lifestyle was associated with shorter baseline LTL among FINGER participants.
“This suggests to us that participants with shorter LTL had more room for lifestyle improvements when they entered the study”, says Dr. Sindi. Adjusting for lifestyle however did not attenuate the observed findings.
Considering that shorter LTL has been associated with poor cognitive performance and dementia, “it is very encouraging that the multidomain lifestyle intervention was especially beneficial among individuals with higher risk” commented the authors.
In the absence of disease-modifying drugs for dementia and Alzheimer’s disease, preventive initiatives have recently gained much attention as a promising intervention approach.
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (led by Professor Miia Kivipelto) is a comprehensive multidomain prevention trial including nutritional guidance, exercise training, computer-based cognitive training, and intensive management of vascular and metabolic risk factors. In this trial, 1,260 older adults (aged 60-77) were randomly allocated to the intervention or control groups (the latter receiving standard health advice). After 2 years, cognition scores (measured by the Neuropsychological Test Battery) were higher in the intervention group for total cognition as well as various cognitive domains (for the main results see Ngandu et al., 2015, The Lancet). This study was the first and largest of its kind, using a multidomain approach, with long follow-up duration and leading to a paradigm shift in the field of dementia prevention.
More recently, researchers in the FINGER team have been investigating the underlying biological mechanisms associated with the positive intervention effects. Dr. Shireen Sindi and colleagues have been examining the role of LTL in the trial.
When telomere length is shortened, their capacities to protect DNA are compromised. LTL is considered a biomarker of aging and aging-related diseases, representing cells’ ‘biological age’ rather than ‘chronological age’.
Previous studies have shown that various lifestyle and psychological factors are associated with shortened LTL, such as unhealthy diets, obesity, smoking, psychological stress, as well as psychiatric and health conditions, while healthy lifestyle factors such as physical exercise are associated with longer LTL.
LTL is also associated with cognition, and patients with Alzheimer’s disease have shorter LTL. These same associations may be found among individuals with mild cognitive impairment.
Despite the observational findings on lifestyle factors, cognitive impairment and LTL, few studies have investigated the role of LTL in the context of clinical trials, and none had focused on cognition as an outcome. This further highlights the value of the current findings from the FINGER trial.
The team is currently investigating the impact of the multidomain lifestyle intervention on LTL among FINGER participants, as this will provide insight on potential methods to enhance LTL.
The FINGER trial was coordinated by the National Institute for Health and Welfare, Helsinki, Finland (trial coordinator: Associate Professor Tiia Ngandu). Telomere length analyses were carried out at the laboratory of Associate Professor Iiris Hovatta at the University of Helsinki, Finland.
The Principal Investigator Professor Miia Kivipelto is affiliated to Karolinska Institute (Sweden), The University of Eastern Finland, the National Institute for Health and Welfare (Finland) and Imperial College London (UK). The current study’s last author Associate Professor Alina Solomon is affiliated to the University of Eastern Finland and Karolinska Institute.
Funding sources included Fonds de la recherche en santé du Québec (FRSQ), the Alzheimer’s Research & Prevention Foundation, Academy of Finland, ALF grants, the Swedish Research Council, Alzheimerfonden, Center for Innovative Medicine (CIMED) at Karolinska Institute South Campus, AXA Research Fund, Knut and Alice Wallenberg Foundation, Stiftelsen Stockholms sjukhem, and Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse.
Sindi S, Ngandu T, Hovatta I, Kåreholt I, Antikainen R, Hänninen T, Levälahti E, Laatikainen T, Lindström J, Paajanen T, Peltonen M, Khalsa DS, Wolozin B, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M, Solomon A; FINGER study group (2017) Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial. J Alzheimers Dis 59, 1459-1470. doi: 10.3233/JAD-170123.
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer's Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 4.151 according to Thomson Reuters' 2014 Journal Citation Reports. The Journal is published by IOS Press (www.iospress.com).